Current Opinion in Allergy and Clinical Immunology 24(3):p 114-121, June 2024. | DOI: 10.1097/ACI.0000000000000987
Nieto-García, Antonio; Nieto-Cid, María; Mazón-Ramos, Ángel
Abstract
Purpose of review
The aim is to update the information currently available for the use of biologics in severe asthma in children, in order to facilitate their prescription as far as possible.
Recent findings
The appearance of biologics for the treatment of severe asthma has meant a revolutionary change in the therapeutic approach to this disease. Currently, five biologics have been approved for severe asthma in children and/or adolescents by the regulatory agencies: omalizumab, mepolizumab, benralizumab, dupilumab and tezepelumab. But despite their positive results in terms of efficacy, there are still relevant points of debate that should induce caution when selecting the most appropriate biologic in a child with severe asthma. Indeed, safety is essential and, for several of the existing treatments, the availability of medium-term to long-term data in this regard is scarce.
Summary
The use of biologics can facilitate the therapeutic paradigm shift from pleiotropic treatments to personalized medicine. However, the choice of the most appropriate biologics remains a pending issue. On the other hand, to the extent that several of the biologics have been available for a relatively short time, the most robust evidence in terms of efficacy and safety in children is that of omalizumab.
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
 |
Virus-free.www.avast.com |
Mastopedia Research Feed 